Page 5 - Randomised Evaluation News Today

sudok1 / iStock Convalescent plasma given to hospitalized COVID-19 patients did not improve survival or rates of release from the hospital within 28 days, need for invasive mechanical ventilation, or death, according to the most recent findings of the Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial in the United Kingdom. The results, published late last week in The Lancet, add to evidence that SARS-CoV-2 antibody-rich plasma taken from COVID-19 survivors doesnt benefit severely ill ...

The study cautions against the use of plasma therapy due to insufficient evidence on its efficacy.

Tocilizumab, like other potential COVID-19 drug treatments, is in spot shortages around the world. In India, its being allocated to states by the government. The UK National Health Service allows patients to receive only one dose. And in Canada, whose use of the drug was the spotlight of a CMAJ analysis yesterday, its considered to be in tier 3 shortage, a status reserved for potential COVID-19 drugs that allows them to be withheld owing to scarcity. Canadas shortage could cause supply and dem...

Published: 12:03 PM March 12, 2021    Dr Jakki Faccenda, respiratory consultant and one of the principal investigators for the study with research nurses. - Credit: NWAFT The North West Anglia NHS Foundation Trust has recruited its 600th patient to the study which is part of a national study into life-saving treatments for Covid-19. The Trust is one of the top 10 recruiting sites for the study, with one in five patients admitted to Hinchingbrooke and Peterborough City hospitals with Covid-1...

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world's largest clinical trial for COVID-19 treatments, has now expanded...

Oxford Universitys COVID-19 therapeutics trial goes global ANI | Updated: Feb 18, 2021 17:57 IST London [UK], February 18 (ANI): A UK trial of potential Covid-19 treatments has started to enroll patients in other countries in the hope of speeding up results, Oxford University said on Thursday. CNN reported that The RECOVERY trial looks at whether existing drugs can be used to treat the virus. The trial has enrolled more than 36,000 hospital patients in the ...

India set for funding wave with flurry of IPOs in 2021 Amazon and Flipkart make up 80% of India’s e-comm market sharePremium 2 min read Share Via Read Full Story India’s internet economy is set to attract massive investments as several players such as food-delivery startup Zomato, courier service provider Delhivery, Walmart-owned Flipkart, and e-tailer Nykaa are expected to enter the public market in 2021. “More than $60 billion has been invested in India’s internet startups in the past...

Researchers may have pinpointed a new treatment method for the coronavirus. A new study says this arthritis medication could prevent you dying from COVID.

email article Tocilizumab (Actemra) showed a slight but statistically significant mortality benefit in critically ill COVID-19 patients, according to a press release from the U.K.s pragmatic RECOVERY trial. Of patients treated with tocilizumab, an IL-6 inhibitor used for rheumatoid arthritis and related conditions, 29% died within 28 days versus 33% of patients treated with usual care (rate ratio 0.86, 95% CI 0.77-0.96, P 0.007), researchers stated. This amounted to a number needed to tr...

Tocilizumab appears to reduce the risk of death in hospitalized patients with severe Covid-19, researchers at the University of Oxford said